Tags

Type your tag names separated by a space and hit enter

Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.
Int J Geriatr Psychiatry 2000; 15(8):713-20IJ

Abstract

The objective of this study was to assess the efficacy of donepezil in patients with mild to moderate Alzheimer's disease (AD) in clinical practice. This was an open-label study in which patients were referred to an elderly mental health clinic in Southampton, UK. Eighty patients with mild to moderate AD received 5 mg/day donepezil for the first 4 weeks, after which, if tolerated, the dose was increased to 10 mg/day. Efficacy and safety assessments were carried out every 3 months. Efficacy was assessed by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Neuropsychiatric Inventory-carer Distress Scale (NPI-D). Mean improvements from baseline were observed at the 3-month assessment on all four efficacy measures. At 3 months, 39% of patients showed an improvement of at least 4 points on the ADAS-cog, and 37% of patients had improved by 4 points or more on the NPI. In those patients who showed improvement and were maintained on donepezil, improvements were sustained for 18 months on the MMSE and NPI, 15 months on the NPI-D, and for 6 months on the ADAS-cog. Six per cent of patients discontinued medication due to adverse events. In a typical clinical practice setting, patients with mild to moderate AD tolerated donepezil well. Clinically meaningful improvements in cognitive function and a reduction in neuropsychiatric symptoms were demonstrated in nearly 40% of patients with associated reduction in carer distress. Continued benefit was seen for up to 18 months in the selected group of patients who initially responded in treatment.

Authors+Show Affiliations

Southampton Memory Clinic, Moorgreen Hospital, Southampton SO30 3JB, UK. memclin@aol.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10960883

Citation

Matthews, H P., et al. "Donepezil in Alzheimer's Disease: Eighteen Month Results From Southampton Memory Clinic." International Journal of Geriatric Psychiatry, vol. 15, no. 8, 2000, pp. 713-20.
Matthews HP, Korbey J, Wilkinson DG, et al. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry. 2000;15(8):713-20.
Matthews, H. P., Korbey, J., Wilkinson, D. G., & Rowden, J. (2000). Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. International Journal of Geriatric Psychiatry, 15(8), pp. 713-20.
Matthews HP, et al. Donepezil in Alzheimer's Disease: Eighteen Month Results From Southampton Memory Clinic. Int J Geriatr Psychiatry. 2000;15(8):713-20. PubMed PMID: 10960883.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. AU - Matthews,H P, AU - Korbey,J, AU - Wilkinson,D G, AU - Rowden,J, PY - 2000/8/29/pubmed PY - 2000/10/14/medline PY - 2000/8/29/entrez SP - 713 EP - 20 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 15 IS - 8 N2 - The objective of this study was to assess the efficacy of donepezil in patients with mild to moderate Alzheimer's disease (AD) in clinical practice. This was an open-label study in which patients were referred to an elderly mental health clinic in Southampton, UK. Eighty patients with mild to moderate AD received 5 mg/day donepezil for the first 4 weeks, after which, if tolerated, the dose was increased to 10 mg/day. Efficacy and safety assessments were carried out every 3 months. Efficacy was assessed by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Neuropsychiatric Inventory-carer Distress Scale (NPI-D). Mean improvements from baseline were observed at the 3-month assessment on all four efficacy measures. At 3 months, 39% of patients showed an improvement of at least 4 points on the ADAS-cog, and 37% of patients had improved by 4 points or more on the NPI. In those patients who showed improvement and were maintained on donepezil, improvements were sustained for 18 months on the MMSE and NPI, 15 months on the NPI-D, and for 6 months on the ADAS-cog. Six per cent of patients discontinued medication due to adverse events. In a typical clinical practice setting, patients with mild to moderate AD tolerated donepezil well. Clinically meaningful improvements in cognitive function and a reduction in neuropsychiatric symptoms were demonstrated in nearly 40% of patients with associated reduction in carer distress. Continued benefit was seen for up to 18 months in the selected group of patients who initially responded in treatment. SN - 0885-6230 UR - https://www.unboundmedicine.com/medline/citation/10960883/Donepezil_in_Alzheimer's_disease:_eighteen_month_results_from_Southampton_Memory_Clinic_ L2 - https://doi.org/10.1002/1099-1166(200008)15:8<713::aid-gps187>3.0.co;2-i DB - PRIME DP - Unbound Medicine ER -